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(57) ABSTRACT 
The invention presents a method designed to simultaneously 
measure certain unsaturated lipids and certain vitamins 
present either as single substances or in complex mixtures 
such as exist in serum and natural oils. Target lipids are free 
cholesterol, unsaturated cholesteryl esters; free polyunsatu-
rated fatty acids, and their esters as triglycerides, and 
phospholipids. Distributions of these analytes over the broad 
range of serum lipoproteins from chylomicrons to high 
density fractions are determined using a procedure that 
involves a single step reaction in which the molecular 
unsaturations are subjected to non-enzymatic color inducing 
reagents. For natural oils and vitamins, the same method 
serves as a quality control procedure. Analytical detection is 
achieved using broad spectrum absorbance and/or fluores-
cence measurements. Measured spectra are aggregates of the 
absorbance contributions from each of the analytes. Data 
analyses follow two paths. One uses raw spectral data. In the 
other, multivariate methods of analysis, particularly princi-
pal component (or factor) analysis, leads to 2-D and 3-D 
clustering correlations which have significant diagnostics 
capabilities for the early detection of human serum disorders 
and for quality control. 
15 Claims, 13 Drawing Sheets 
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DIRECT SERUM LIPIDS ASSAYS FOR 
EVALUATION OF DISEASE STATES 
CROSS REFERENCE TO RELATED 
APPLICATION 
This application claims benefit of U.S. provisional patent 
application Serial No. 60/266,541, filed Feb. 5, 2001, the 
disclosure of which is incorporated herein by reference. 
BACKGROUND OF THE INVENTION 
In U.S. Pat. Nos. 5,593,894 and 5,989,916, incorporated 
herein by reference, speciation of serum cholesterol over the 
very low density lipoprotein (VLDL), low density lipopro-
tein (LDL), and high density lipoprotein (HDL) fractions 
was done in a direct manner based upon a multivariate 
analysis treatment of visible absorbance data produced by 
simultaneous color derivatizations of the serum cholesterol 
lipoprotein subfractions. Total serum cholesterol (TC) was 
determined as the sum of the amounts in each fraction. 
The preferred procedure, as presented in the above ref-
erenced patents, for the direct assay of cholesterol was to 
react a 10 µL aliquot of serum with 1.0 mL of a reaction 
mixture comprised of an acylating compound having the 
general formula R.CO.R1 , wherein R1 is halogen, R is 
selected from the group of lower alkyl radicals, and a 
predetermined amount of perchlorate ion effective enough to 
form a spectrophotometrically active product with choles-
terol. The perchlorate was selected from a group consisting 
2 
acids or as esters of cholesterol, glycerol, and phospholipids. 
Esters are the predominant forms for LCFA's in blood. 
Amounts of free acid forms of LCFA's are, in general, very 
small. Taken altogether, the assay of each individual analyte 
5 would constitute a comprehensive screening of serum lipids from a single experimental test. 
LCFA's, and their ester derivatives, are both saturated and 
unsaturated. In natural forms the sites of unsaturation are 
cis-ethylenic double bonds, i.e. -CH=CH-. The number 
of double bonds ranges from one, for a series of monoun-
10 saturated fatty acids (MUFA's), of which oleic acid is the 
predominant example, to polyunsaturated fatty acids 
(PUFA's), represented by linoleic acid with 2 and eicoso-
hexaenoic acid with 6 all cis- double bonds. 
2. Extended Lipid Analyses 
15 It was determined that the chromogenic acylating reagent (s), originally thought to be selective to only cholesterol, is 
also selective towards particular -CH=CH- double 
bonds that are present in both cyclic and open chain aliphatic 
molecular structures. In serum, therefore, the actual number 
of lipid analytes that do react with the acylating reagent is 
20 extended to include free cholesterol (FC); saturated and 
unsaturated cholesteryl-LCFA esters (CE); free LCFA's 
themselves; and LCFA's in the form of triglycerides (TG) 
and phospholipids (PL), both of which are unsaturated 
LCFA esters of glycerol. Saturated LCFA's do not react. 
25 A red color, which is typical for standard reference 
materials (SRM's) for FC and CE, is a product of reactions 
with the /15 carbon-carbon double bond in ring B of the 
steroid structure. Colors from reactions with carbon-
carbon double bonds in SRM forms of open chain LCFA's, 
in contrast, are yellow to pale orange. When SRM forms of 
30 cholesterol and LCFA are mixed and reacted in vitro, the 
color is an aggregate of red and yellow with the shade of 
orange being determined by the proportions of each com-
ponent and the relative absorbance intensity of each chro-
of barium perchlorate, zinc perchlorate, and perchloric acid. 
For the preferred acylating compound the R group was 
methyl, the R1 was chloride ion, and the preferred perchlo-
rate was either HC1O4 or Zn(ClO4 ) 2 .6H2 O. Three spectral 
detection methods (absorbance, fluorescence, and circular 
dichroism) were described as being suitable for the mea-
surement of the color intensity as a function of wavelength 
after a fixed time (usually 15 minutes). Absorbance detec- 35 
tion was the preferred choice. 
mophore in the products from the simultaneous acylations. 
Every one of the colored products from the reactions with 
cholesterol analogs and PUFA analogs fluoresces. Emission 
fluorescence spectroscopy is an alternative detector to absor-
bance although less easy to use and interpret. The choice of an acetyl chloride with either perchloric 
acid or zinc perchlorate hexahydrate reagent constitutes only 
one of many. Alternative reagent mixtures, not addressed in 
earlier patents, convey similar information for cholesterol 
and, in certain cases, additional information for other serum 
lipids besides cholesterol in a single simultaneous test. 
Alternative reagent compositions are specified in detail in 
this disclosure as are some options where added modifiers, 
in particular glacial acetic acid and acetic anhydride, can 
enhance the spectral data and give better control over the 
experimental reproducibility. 
These same primary lipids occur in serum where they are 
40 distributed over the chylomicron, VLDL, IDL, LDL, and 
HDL lipoprotein fractions and subfractions, in different 
proportional amounts. These lipids together with apolipo-
proteins and other lesser components in variable amounts, 
determine the relative densities of the individual lipoprotein 
45 
particles which is a common basis for their physical dis-
tinctions. Colors observed from acylations of synthetically 
prepared serum lipoprotein fractions, progress from being 
predominantly yellow ( chylomicrons) through orange 
(VLDL, IDL) to pink (LDL, HDL), as the LCFA amounts Data analyses claimed in U.S. Pat. Nos. 5,593,894 and 
5,989,916 were limited to the simultaneous assays of three 
cholesterol variables, namely VLDL-C, LDL-C, and HDL- 50 
C, using absorbance data at only five wavelengths and the 
single reagent system, acetyl chloride and HC1O4 catalyst. 
TC values were calculated as the sums of the parts. 
decrease and the cholesterol amounts increase. 
An analogous color variation is seen to occur for acyla-
tions of synthetic mimics of the Type I, Ila, Ilb, III, IV, and 
V dyslipidemias. On the basis of quantitative interpretative 
analysis of the absorbance spectra associated with the result-
ant aggregate colors for these mixtures, the opportunity is Implications that other serum lipids ( e.g. triglycerides and 
free fatty acids) are involved in the genesis of coronary heart 
disease (CHD), and appear to react with the same deriva-
tizing reagent, stimulated the need for developing broader 
simultaneous assays of multiple variables but still using a 
single experimental procedure. 
55 presented to determine the amounts of each individual lipid 
in real serum samples with the same dyslipidemic designa-
tions. 
3.Assay Procedure 
SUMMARY OF THE INVENTION 
The assay procedure of the present invention is performed 
60 in three general steps: 
1. Objects 
The object of the present invention is to expand the 
diagnostic capabilities of the technology from being only a 
serum cholesterol lipoprotein profile to a much broader 
serum lipids assay. The focus is on serum (or plasma) 65 
cholesterol and its analogs, and on serum (or plasma) long 
chain fatty acids (LCFA's) that are present either as free 
subject the lipids in a small volume aliquot of serum 
(plasma) to simultaneous selective acylations using a 
preferred color inducing reagent; 
measure absorbance and/or fluorescence spectral data for 
the colored products over the entire visible wavelength 
range using a fast scanning spectrophotometer or spec-
trofluorimeter; 
US 6,737,275 B2 
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tonically with time for the methyl linoleate but passes 
through a maximum value after 3-4 minutes for cholesterol. 
This difference in behavior simplifies their distinction. 
FIG. 8. Absorbance spectra vs. time measured for methyl 
determine the amount of each lipid, and/or the propor-
tionate amount of each lipoprotein particle in the serum 
lipid profile using a combination of multiple wave-
length detection with modern multivariate statistical 
analyses methods. 
4. Object of the Invention 
5 linoleate (lower series) and for conjugated methyl linoleate 
(upper series). The catalyst is 70% pechloric acid. The 
increase is monotonic for the unconjugated ester and non-
monotonic for the conjugated ester. This is sufficient evi-
dence to characterize each isomer. 
While there have been other attempts to routinely measure 
total serum cholesterol and total TG in a simultaneous assay, 
there have been none where the focus of the assay was on 
either the total unsaturated lipids or the discrimination 10 
between cholesteryl and glyceryl based esters. 
Although all serum lipoprotein fractions are composed 
from the same, relatively few, fundamental lipids, and differ 
only in their relative proportions in each lipoparticle, there 
is more than sufficient evidence from the subtle differences 15 
observed in the multiplexed spectral data to believe that a 
clinical diagnostic procedure has been developed that dis-
criminates among the different serum dyslipidemias and 
diabetes. Its ultimate proof will depend upon the creation of 
a comprehensive library of spectral data for as broad a cross 20 
section of the general population as possible. The library 
will have sufficient number representations from normal and 
all forms of abnormal lipidemias and be a comprehensive 
resource from which can be derived more dependable, and 
more meaningful, risk factor models for the early assessment 25 
and prediction of coronary heart disease (CHD) and diabe-
tes. 
BRIEF DESCRIPTION OF THE DRAWINGS 
FIG. 9. Absorbance spectra for eight serum samples with 
LDL-C values equal to 169 mg/dL. Differences throughout 
the spectrum, and particularly in the 370-480 nm range, 
correlate with the relative amounts of PUFA's in the form of 
triglycerides and phospholipids. Spectra for subjects that are 
diabetic show a low maximum absorbance around 420 nm. 
FIG. 10. Full spectrum cross-correlation plots for: a 
normal serum vs. a second normal serum (top); the same 
normal serum vs. the serum for a Type I dyslipidemia subject 
(middle); the same normal serum vs. serum for a diabetic 
subject (bottom). 
FIG. 11. A square matrix composed of a network of binary 
cross-correlation plots wherein 370---480 nm spectral data for 
each entry are simultaneously compared with all of the 
others. In making a preliminary diagnostic decision on a 
subject with unknown lipidemia, data are entered in the top 
left cell and cross-correlations are made against data for 
each type of dyslipidemia. The cell with the cross-
correlation coefficient closest to 1.0 in the Variables Table is 
FIG. 1. Absorbance spectra for a series of unsaturated 
lipids where the color inducing reagent is AC+ 70% perchlo-
30 statistically the most likely diagnosis. In this particular 
example, the diagnosis is a Type Ilb dyslipidemia. 
FIG. 12. Upper plot is a cluster diagram that correlates 
spectra for sera with similar lipids proportions in 2-D space. 
The coordinate axes are the two most sensitive principal 
ric acid. In order of decreasing intensity at 520 nm, the 
unsaturated lipids are: cholesteryl arachidonate; free choles-
terol; serum; cholesteryl linoleate; cholesteryl myristate; and 
glyceryl trilinoleate ( a TG mimic). 
FIG. 2. Absorbance spectra for a series of unsaturated 
lipids where the color inducing reagent is AAH+ 
concentrated sulfuric acid. In order of decreasing height at 
620 nm, the unsaturated lipids are: cholesteryl pelargonate; 
free cholesterol; serum; and cholesteryl oleate. 
35 components derived from a PCA of the spectral data from 
360-480 nm. Different lipid types are identified by: Y 
(normal); X (Type I); small square (Type II); large open 
square (Type III); triangle (diabetic). Lower drawing is a 
spinning plot diagram that correlates the same spectra for the 
FIG. 3. Absorbance spectrum for a serum sample mea-
sured where the color inducing reagent is AC+0.lM zinc 
acetate. 
40 same sera in 3-D space and separates the "overlapping" 
clusters in the 2-D plot. Symbols used in the upper plot are 
repeated. The third axis is the third most sensitive principal 
component. 
FIG. 13. Cluster diagram correlating spectra for PUFA's 
45 by their similar unsaturations. The diagram includes SRM's 
and natural oils. The coordinate axes are the two most 
sensitive PC's derived from a PCA of the spectral data from 
360-480 nm in 10 nm increments. Isolated points are for 
FIG. 4. Absorbance spectra for a single serum sample 
measured where the color inducing reagent is a series of 
mixtures of AAH+AC that are 100%, 75%, 50%, 25%, and 
0% ofAAH from left to right. The catalyst is 70% perchloric 
acid. As the proportion of AC is increased the absorbance 
band around 400 nm decreases in intensity and the 520 nm 50 
band increases in intensity. Low levels of AC suggest 
reaction with only PUFA's. 
FIG. 5. Absorbance spectra for a series of five serum 
samples where the color inducing reagent is a 3:2 mixture of 
AC: 1,2-dichloroethane. The acid catalyst is 70% perchloric 55 
acid. 
FIG. 6. Absorbance spectra for a series of PUFA methyl 
esters where the color inducing reagent is AC+ 70% perchlo-
ric acid. In order of decreasing intensity at 375 nm, the 
PUFA's are: conjugated methyl linoleate; methyl 60 
eicosohexa-enoate; methyl linoleate; methyl eicosopen-
taenoate; methyl linolenate; and methyl arachidonate. 
FIG. 7. Absorbance spectra measured at 1 minute inter-
vals up to 15 minutes for free cholesterol (major band 
maximum at 520 nm) and methyl linoleate (major band 65 
maxima at 370 and 410 nm). The reagent is AC+perchloric 
acid. Absorbance in the 370-410 nm range increases mono-
conjugated methyl linoleate (+) and gamma-linolenate (X). 
DETAILED DESCRIPTION OF THE 
PREFERRED EMBODIMENT 
Chemistry of the Color Reaction 
Introduction 
It is submitted that any Friedel-Crafts (F-C) acylating 
reaction, catalyzed by the addition of any Lewis or Bronsted 
acid, could conceivably be used to produce colored products 
when reacted with SRM's of cholesterol and PUFA analogs. 
Historically the preferred acylating agents are glacial acetic 
acid, acetic anhydride, acetyl chloride, and benzoyl chloride; 
the preferred Lewis acids are ions Al, Sn, Ba, and Zn; and 
the preferred Bronsted acids are the mineral acids HCl, 
HC1O4 , HNO3 , H2 SO4 , and H3 PO4 . 
1. Mechanism 
The mechanism of the color inducing reaction described 
in the incorporated prior patents, in which the reagents are 
acetyl chloride, CH3 CO.Cl, and a Lewis acid (zinc or barium 
US 6,737,275 B2 
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perchlorate) fits the literature description of a F-C acylation 
reaction. Under certain reaction conditions the CH3 CO• 
radical will replace hydrogen from alcohol (-OH) and 
amine (-NH2) functional groups with the elimination of 
HCl. Acylation protects terminal amine groups in peptides 5 
and proteins, prior to their separation by HPLC. As a general 
rule these acylations do not produce colored products. 
Under different experimental conditions the CH3 CO• 
radical and the c1- ion can be made to add across a 
carbon----carbon double bond (-CH=CH-). For this to 
10 
occur, however, at least one methylene (-CH2-) group 
must be in a position that is a to the double bond. The 
minimum molecular structural requirement for the reaction 
to occur, therefore, is (-CH=CH-CH2-). It is specu-
lated that a free radical is produced at the carbon of the 
methylene group that initiates a subsequent propagation 15 
reaction leading to extended conjugation and colored chro-
mophores that absorb energy in the visible spectral range, 
detectable by absorbance, fluorescence, and circular dichro-
ism. A totally conjugated polyene structure would not react 
by this proposed mechanism since the necessary methylene 20 
group is not present. 
For FC under the appropriate reaction conditions, acyla-
tion would occur at the -OH group in the 3~-position, and 
at the /15 -double bond that is adjacent to a -CH2- group 
in the B-ring. In support of this contention, sitosterol and 25 
stigmasterol, both /15 -plant sterols, were the only two from 
a wide selection of twenty or more possible interfering 
steroidal molecules that produced an analogous color reac-
tion. Other biologically important compounds that react to 
produce a color are the A, D3 , and K vitamins, which are 30 present in such small quantities in serum to be below their 
detection limits. 
For 3~-saturated cholesteryl esters, e.g. laurate, myristate, 
pelargonate, stearate, etc., only the /15-double-bond is acy-
lated. The assay will not detect saturated acids. 
For 3~-MUFAand PUFAesters of cholesterol, e.g. oleate, 35 
linoleate, linolenate, arachidonate, eicosopentaenoate, 
eicosohexanoate, etc., acylations occur at the /15 -double 
bond of the cholesteryl moiety and at all of the 
-CH=CH-CH2- groups in the LCFA's. 
6 
2. Alternative Acylating Agents 
Glacial acetic acid (GAC), acetic anhydride (AAH), and 
acetyl chloride (AC) are three suitably safe acylating 
reagents for routine reactions with cholesterol and PUFA 
analogs. The acylating "strength" increases in the order 
GAC<AAH<AC. The second essential ingredient is the acid 
whose function is believed to be catalytic since it is present 
in non-stoichiometric proportions. 
The preferred reagent(s) identified in the incorporated 
references are: 
( a) AC+ 70% perchloric acid, and 
(b) AC+zinc perchlorate hexahydrate. 
These can be classified by the nature of their acids as 
Bronsted and Lewis acid reactions respectively. 
Other reagents that function almost as well and, in one 
instance at least, perhaps even better than (a) and (b), include 
the following: 
(c) AC+l,2-dichloroethane+ 70% perchloric acid 
( d) AC+concentrated sulfuric acid 
( e) AC+methanesulfonic acid 
(f) AC+zinc organic acid salts: acetate, gluconate, meth-
oxygluconate 
(g) AAH+ 70% perchloric acid 
(h) AAH+concentrated sulfuric acid 
(i) AAH+AC+70% perchloric acid 
(d) AAH+AC+concentrated sulfuric acid. 
GAC, by itself, is of insufficient "strength" to acylate the 
-CH=CH-CH2- groupings. It does however have the 
valuable asset of causing an ongoing reaction, initiated by 
AC or AAH, to immediately cease when it is added at, or 
prior to, the chosen end point time for the color incubation. 
Spiking with a small aliquot of GAC is recommended 
whenever emission fluorescence detection is used since data 
accumulation is slower than it is in absorbance detection. 
The mixed acylating reagents (i) and G) produce a series 
of absorbance spectra from serum assays that progressively 
vary with the proportions of AAH to AC. This property 
could conceivably be manipulated to effectively "separate" 
the FC/CE absorbance component from the LCFA compo-
nent as an aid to assaying individual lipid amounts. In 
routine measurements on serum the two assays would be run 
in parallel using different reagent compositions. A similar 
effect is observed for reagent (f) where the spectra for the 
products vary with the absolute amount of zinc acetate 
added. 
Reactions that involve Lewis acid catalysts bear a resem-
blance to F-C reactions. Catalysis by Bronsted acids is 
These same LCFA's form esters with glycerol and are 40 
majority components in the molecular structures of serum 
TG and PL. In general, natural forms of the acids are all 
cis-isomers. trans-isomers are introduced to blood through 
dietary pathways. In TG at least one of the three LCFA ester 
groups is unsaturated. PL are also triesters, two of which are 45 
LCFA esters, saturated and/or unsaturated. The third ester 
grouping in PL is one of several substituted mono-
phosphatidyl esters of glycerol that include choline, inositol, 
and serine. Even if they react, these non-LCFA substituents 
50 
entirely consistent with the use of concentrated H2SO4 as a 
component of the chromogenic Liebermann-Burchard (L-B) 
reagent (7-9), that typically was a 60:30:10 mixture of 
GAC, AAH, and concentrated H2 SO4 . Until fairly recently 
the L-B reagent was widely used commercially to determine 
do not produce a colored product. 
Double bonds in naturally occurring PUFA esters are 
generally unconjugated and increase in number as the num-
ber of carbon atoms in the LCFA chain increases, one for 
oleate, two for linoleate (or w-6 FAE), and its trans-isomer 
linolaiate, three for linolenate (or w-3 FAE) and its conju- 55 
gated geometric isomers, four for arachidonate, and five and 
six for the eicoso-derivatives respectively. On average PUFA 
esters amount to almost 87% of the total LCFA's in serum 
TG. In the context of serum lipids assays therefore, oleate, 
linoleate, and linolenate and, to lesser amounts, higher 60 
conjugated and higher unconjugated PUFA esters of TG and 
PL in serum, are susceptible to acylation by the second 
mechanism. 
serum TC. The mixtures used for this invention are safer to 
use and more stable. 
SUMMARY OF ASPECTS OF THE PRESENT 
INVENTION 
1. Molecular Requirements for Color Reactions 
(1) In the context of being able to produce a color, reagents 
used for these assays are best described as being selective 
towards a particular double bond arrangement, that is 
commonplace in lipids molecules, rather than to only a 
particular compound, e.g. cholesterol. The high incidence of oleic, linoleic, and linolenic esters 
in natural vegetable oils makes them accessible to quality 
control testing using the same reagents and assay proce-
dures. 
65 (2) A mechanistic requirement of the reaction is that at least 
one -CH2- group be in a position that is a- to the 
double bond. The fundamental reactive centers are typi-
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cally (-CH=CH-CH2-) and (-CH2-CH=CH-
CH2-) for unconjugated systems and (-CH2 -
CH=CH-CH=CH -CH2-) for conjugated systems. 
(3) The active functional groups in (3) can be located in 
either cyclic, e.g. in the B-ring of cholesterol, or in long 5 
straight chain aliphatic structures, as they are in LCFA. 
( 4) The initial step in the color reaction is an acylation that 
begins with the addition of a CH3CO•+ radical to a 
C-atom of the double bond. Exact details of subsequent 
steps are obscure but appear to involve the formation of 10 
a free radical on the methylene C-atom followed a pro-
gression of propagation steps that lead to a number of 
poly-unsaturated colored product molecules that have 
extended conjugations. 
2. Acylating Reagents and Reagent Compositions 15 
(5) GAC, AAH, and AC were preferred choices taken from 
a wide selection of potential acylating reagents that also 
included: benzoyl chloride, palmitoyl chloride, succinyl 
chloride, cyclohexanyl chloride, chloroethyl-oxoacetate, 
ethyl-4-chloro-4-oxobutyrate, ethylchloroformate, acry- 20 
loyl chloride, etc. The others were eliminated for various 
incompatibility reasons such as insolubility, 
immiscibility, zero color production, and a too violent 
reaction on mixing with the water introduced by the acid 
8 
spectra are most sensitive to changes in the FC, CE and 
LCFA identities and relative proportions. 
(16) Absorbance spectra for a number of PUFA's including 
both conjugated and unconjugated isomers of the same 
LCFA are very characteristic making it possible to dis-
tinguish one from the other (FIG. 6). 
(17) Absorbance spectra for synthetic mixtures of SRM's of 
unsaturated lipids are weighted aggregates for the spectra 
for individual standards. 
(18) All of the colored products formed from reactions with 
all of the acylating reactions fluoresce. Inventive aspects 
(1) through (17) therefore apply to excitation and emis-
sion fluorescence spectral measurements. 
(19) The combination of absorbance and fluorescence spec-
tral detection data might expand the discriminatory capa-
bilities of the method without changing the chemistry. 
Combination of both detectors on a single instrument is a 
feasible commercial option. 
(20) Injection of a small volume aliquot of GAC to the AC 
reagent mixtures, 111.2 ( a-f), causes the color reaction to 
immediately cease. Elimination of further color develop-
ment gives better control and improved accuracy for 
spectral measurements, and is especially needed for fluo-
rescence detection. 
by an aliquot of serum. 25 (21) Repeated fast scan absorbance spectral measurements 
made at one minute intervals, up to and including the end 
point of the color reaction, produce kinetic data that, with 
the appropriate treatment, will expand upon the discrimi-
(6) The color reagent, AC+HC1O4 (or Zn(ClO4) 2) that was 
claimed to be unique for the assay of serum cholesterol in 
U.S. Pat. No. 5,989,916, (FIG. 1), is only one of several 
generic F-C and related acylating reagents that function in 
analogous ways. Experimental spectral data are included 30 
in FIG. 1 for SRM's. 
(7) In support of the statement in ( 6), experimental absor-
bance spectral data are included for products from serum 
reactions with AAH+H2S04 (FIG. 2). 
nation capabilities of the method without changing the 
chemistry (FIG. 7). 
The special attributes that make better discriminations 
possible are: (i) the rates for LCFA acylations are much 
faster than the rates for FC and CE acylations; and (ii) during 
the times taken for colors to develop, absorbances in the 
(9) In support of the statement in ( 6), experimental absor-
bance spectral data are included for products from serum 
reactions with AC+Zn(CH3 COO)2 (FIG. 3). 
35 range 360---480 nm pass through a maximum value after 
different times for each lipid. The latter is especially true for 
conjugated vs. unconjugated lipids (FIG. 8). 
(10) In support of the statement in (6), any of the reagents 4. Spectral Data Analyses and Diagnostic Evaluations 
(a) Untreated (Raw) Spectral Data (b) through ( e ), listed above, can be modified by adding 
a third component such as chloroform, 1,2-
dichloroethane, and GAC that will provide either better 
control of the reactions for fluorescence detection, or 
better discriminations among the analytes (FIG. 4). 
40 (22) The raw spectrum for a serum sample, or any synthetic 
mixture, is a permanent snapshot record of the relative 
proportions of the unsaturated constituents of cholesterol 
and/or LCFA lipids at a given time. 
(11) In support of the statements in (6) and (10), experi-
mental absorbance spectral data are included for products 45 
from reactions with the ternary reagent AC+AAH+ 
perchloric acid which has the potential to experimentally 
"separate" the PUFA spectra from the total serum spectra 
by changing the proportions of acetyl chloride to acetic 
anhydride (FIG. 5). 
(12) Advantages that accrue to using AAH over AC are that 
the anhydride is less volatile and safer to handle. But more 
importantly, on their hydrolysis by the water introduced 
via serum and 70% HC1O4 , no HCl is evolved. 
50 
(13) Advantages that accrue to using the AC+zinc organic 55 
acid reagents are that the precipitation of serum proteins 
and the liberation of HCl gas are both minimal. 
3. Spectral Data 
(14) For any of the given reagents, the major absorbance 
bands in the spectra for colored derivatives of SRM's of 60 
cholesterol and its esters occur at wavelengths longer than 
the major bands for colored derivatives of SRM's of 
MUFA and PUFA's whether they are in the forms of free 
acids or esters of cholesterol or glycerol. (Table 1 ). 
(15) Significant overlap of the typically cholesterol spectra 65 
and the typically LCFA spectra occurs over the spectral 
range 350---480 nm. It is in this range that the absorbance 
(23) A collection of these spectral snapshots measured for a 
broad representative cross section of the population at 
large, will serve as the basis library set for an entirely new 
approach to deriving prediction models for the early 
detection of dyslipidemias, coronary artery disease, and 
diabetes (FIG. 9). All of the subjects whose spectra appear 
in FIG. 9 had LDL-C values equal to 169 mg/dL. The 
variabilities are accountable by changes in the other 
lipoprotein cholesterol values and the differences in the 
PUFA contents of TG and PL. 
(24) The fact that these same targeted unsaturated centers are 
labile to oxidation, the same basis set of raw spectral data 
in (23) could also be used in a new approach to deriving 
prediction models for the early detection of oxidative 
stress. 
(25) As a first test of (23), full spectral data from exploratory 
clinical trials on 94 subjects demonstrated that direct 
pair-wise 2-D cross correlations do exist between raw 
spectral data and serum dyslipidemias including diabetics 
(FIG. 10). Of the 94 subjects, 12 were evaluated as 
normal, 2 were Type I, 11 were Type Ila and Ilb, 9 Type 
III, and 60 diabetics. 
(26) For a more general first step diagnosis, the spectrum for 
a subject with a suspected dyslipidemia can be added to 
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a broad cross-correlation matrix diagram where it can be 
compared with representative spectra for all dyslipidemia 
types (FIG. 11). The best "diagnostic" match is derived 
from the matrix coordinates where the correlation variable 
10 
(31) Because of (29), not one person would be disqualified 
when choosing a cohort from local, regional, national, or 
international community, because of an arbitrarily 
imposed upper limit on any blood component. 
is closest to 1.0. The sensitivity of the correlation vari-
ables are enhanced if the "full" spectral data are reduced 
to only the 360---480 nm wavelength range where the 
spectra of the cholesterol and PUFA analogs overlap. 
(b) Statistically Treated Spectral Data 
5 (32) Because of (29), conclusions from multivariate statis-
tical analysis data treatments, such as ANN and principal 
component analysis (PCA), which are used in this 
invention, are not biased by the elimination of individuals 
at high risk. 
(27) The raw spectral data for the limited wavelength range 10 (33) The combination of multiple wavelength detection and 
multivariate data analysis eliminates every need to physi-
cally separate serum lipoprotein fractions either by selec-
tive precipitation, based upon their relative densities, or 
in (26) for the same 94 subjects in (25) were subjected to 
tests using multivariate principal component analysis 
(PCA) algorithms. All 94 spectra, composed of 65 absor-
bance values, could be fitted by 8 principal components 
(PC's). By correlating the PC's in pairs or in triads, the 15 
relationships among all of the spectra could be simulta-
neously expressed in 2-D and 3-D clustering diagrams, 
(FIG. 12). The confidence level (perimeter) for the 2-D 
elliptical-clustering discriminations is set at 90%. 
Correct correlations of points with particular lipidemia 20 
groupings are predicted for 9 of the 12 "normals"; 2 of 2 
Type I; 9 of 11 Type II; 6 of 13 Type III, and 52 out of 60 
diabetics, for a total correct assignment ratio of 78/96, or 
81.3%. The success ratio is increased when the 3rd dimen-
sion is added in the Spinning Plot presentation, (FIG. 12). 25 
The 3rd dimension shows the spatial (along the z-axis) 
separation of clusters that appear to overlap in 2-D where all 
the clusters are projected on to an x-y plot. A caveat in regard 
to the data treatment as it is presented in the FIGS. (10-12) 
is the fact that a few Type II and Type III patients were 30 
already on lipid-lowering drug treatments at the times the 
samples were collected. Predictions for these patients, there-
fore are skewed towards the "normal" lipidemia grouping. 
With better control of patient selection higher success rates 
are anticipated. 35 
This diagnostic procedure is unique in that the usual 
variables TC, TG, VLDL-C, LDL-C, and HDL-C are not 
involved in any way in arriving at "diagnostic" predictions. 
Cholesterol and Serum Lipoproteins 
(28) Resorting to the more common practice of measuring 40 
lipoprotein cholesterol profiles, VLDLl-C, VLDL2-C, 
IDL-C, LDL-C, and HDL-C, were determined spectro-
scopically for 36 subjects using artificial neural network-
ing (ANN) algorithms to treat absorbance data in the 
spectral range 350-480 nm. TC is calculated as the sum 45 
of the parts. All of the lipofraction cholesterols are mea-
sured directly and with equal accuracy and precision. To 
correlate these numbers with results from a conventional 
assay, the same cholesterol profiles were measured by 
sequential ultracentrifugation. Linear regression equa- 50 
tions for correlations between methods are: y=0.993x+ 
3.27 for TC; y=0.906x+0.83 for VLDLl-C; y=0.965x+ 
1.62 for VLDL2-C; y=0.910x+2.30 for LDL-C; 
y=0.903x+4.75 for HDL-C. 
(29) In this invention there is no apparent limit imposed by 55 
the serum TG level, of the Friedewald equation. Spectra 
for subjects whose TG values exceeded 3000 mg/dL are 
measured with equal precision. 
(30) Because of (29), nowhere in the development of the 
procedures in (23-27) is any individual excluded in 60 
compiling an unbiased basis set for CHD risk prediction 
models which is in stark contrast to the limiting approxi-
mations imposed on TG ( <400 mg/dL) and VLDL-C 
( = TG/5) in the Freidewald equation. Their inclusion 
means that any derived prediction models are not subject 65 
to arbitrary biases created by the selective exclusion of 
high risk patients. 
by ultracentrifugation, based upon their relative flotation 
properties, e.g. the ~-quantification method. 
PUFA's in Reference Materials and in Natural Oils 
(34) Statistically untreated spectra and PC-correlation plots 
have enough discriminatory power to distinguish between 
cis- and trans-geometrical isomers, between positional 
isomers, e.g. w-3- and w-6-linolenic acids, and between 
conjugated and unconjugated isomers. Being able to 
experimentally discriminate between conjugated and non-
conjugated isomers of PUFAesters with equal numbers of 
C-atoms is an elementary procedure and provides for a 
new and important routine analytical method for their 
assays, either separately or in many component combi-
nations (FIG. 6). The test has potential clinical signifi-
cance in the measurement of oxidative stress. 
(35) A PCA of absorbance spectra measured with a 2 nm 
resolution from 350-750 nm for SRM's of PUFA's in the 
form of free acids, their cis- and trans-methyl esters, and 
glyceryl esters, combined with spectral data for pure 
samples of olive, soybean, safflower, sunflower, and fish 
oils reduces the full spectral data of 200 data points to 
only 8 principal components (PC's). 2-D and 3-D clusters 
made from the most significant PC's shows strong spec-
tral correlations between the pure species and their pres-
ence in mixtures (FIG. 13). Any deviation from the 
clusters are clear evidence that a pure natural oil has been 
contaminated making this a probable quality control 
assay. 
Synthetic Lipoproteins and Synthetic Dysplipidemias 
(36) Absorbance spectra for solutions of synthetic lipopro-
teins prepared to mimic serum chylomicrons, VLDL, 
IDL, LDL, and HDL particles using literature values for 
the relative amounts of FC, its saturated and unsaturated 
esters, triolein and triolenin as TG mimics, and egg 
lecithin to mimic PL, correlate very well with experimen-
tally measured data. 
(37) Absorbance spectra for solutions of synthetic dyslipi-
demias prepared to mimic Types I, Ila, Ilb, III, IV, and V, 
prepared by mixing synthetic lipoproteins from (36) 
according to published literature proportions, correlate 
very well with spectra measured for serum samples that 
were clinically confirmed to be from each type. 
These 37 items constitute a compendium of original 
aspects that are associated with the invention. These aspects 
cover the general choice of the derivatization reagent of 
which there are several; the necessary structural properties 
of the analytes that are susceptible to the selected reagents; 
the spectral properties of the colored products from reactions 
with both SRM's and with mixtures of various lipids; 
interpretations of spectral data by the application of multi-
variate statistical analyses methods that include artificial 
neural networking, principal component analysis, and 2-D 
and 3-D clustering correlation algorithms; and how the 
whole package can be applied to (1) the diagnoses of lipids 
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related disease states, (2) to the development of prediction 
models for heart disease and oxidative stress, (3) to the assay 
of natural oils and vitamins and, ( 4) to the analytical 
distinction among the various isomeric forms of PUFA's. 
12 
the proportions of the components employed in preparing 
the reagent. When batching samples for assay, care must be 
taken to ensure that the final color is stable beyond the 
endpoint time. Reactions that might continue after the end-
DETAILED PROCEDURE FOR THE ASSAY s point involve sera where TC and TG are very high. In those 
cases the addition of 10-25 µL of GAC at the prescribed 
endpoint will bring the reaction to an immediate stop, a 
function that is necessary if fluorescence is the detector of 
The preferred binary and ternary reagent solutions are 
prepared in situ. For Bronsted acid reagents, the volume 
ratio of acid to acylating agents is 1:40. Although it can be 
added in solution, the Lewis acid Zn salts are better added 10 
as a weighed aliquot such that the ratio of acid to acylating 
agent is again approximately 1:40. Small variations from the 
exact numbers are permissible from one reagent to another 
in order to optimize the relative absorbance intensities of the 
color(s) and to enhance the discriminations among analytes. 1s 
Volume ratios of acylating agents to modifier additive are 
dictated by the mutual solubilities the solvents involved and 
by the quality of the spectra and can be varied over the range 
1/4 to 4/1. 
choice. 
Factors in the assay are the ratios of sample to acylating 
agent to acid catalyst. This description, as it is written here, 
is based upon a 10 mm pathlength, narrow window, cuvet 
configuration. Temperature control is not a requirement. 
Absorbance maxima, measured at 360 nm and 520 nm, 
range from 0.25 to 1.5 absorbance units. Quantities can be 
reduced in size to satisfy different instrumental 
configurations, reduce the cost per sample, and alleviate 
disposal of the spent reagent. To preserve the 0.25-1.5 
For the color reaction, 1.0 mL of the acylating agent is 
added to a 10-25 µL aliquot of fasting serum or oil sample. 
Precipitated materials, when they occur, are separated either 
20 absorbance range, concentrations may have to be increased 
to accommodate a shorter pathlength, but reagent ratios 
should be maintained. Reagents are disposed of in water or 
dilute alkali solution by low speed centrifugation or by filtration depending upon 
the reagent mix. The supernate is transferred to a 10 mm 
pathlength cuvet and the absorbance spectrum measured 25 
over the visible wavelength range 350-800 nm using a rapid 
scanning, preferably diode-array, spectrophotometer. The 
spectrum for reagent without added serum is used for the 
baseline correction. A diode-array instrument is almost man-
datory if spectra are measured at one minute intervals over 30 
the development time to acquire kinetic information because 
Serum lipid 
Cholesterol 
Cholesteryl esters (satd.) 
Cholesteryl linolenate 
Cholesteryl linolenate 
Cholesteryl arachidonate 
Spectral data are archived in computer files. Data treat-
ments involve multivariate statistical analysis software 
packages. Diagnostic correlation procedures rely upon clini-
cal information and data measured independently and done 
according to standard reference procedures. Many software 
programs are commercially available to handle the specifics 
of the analyses. 
TABLE 1 
Wavelengths of band maxima Relative intensities 
520 nm Strong 
362, 404, 420(sh) nm Moderate! y weak 
520 nm Strong 
362, 402(sh), 420 nm Moderate! y weak 
520 nm Strong 
362, 402(sh), 420 nm All moderately weak 
520 nm Strong 
362, 406(sh), 424(sh), 440 nm All moderately weak 
524 nm Strong 
364, 400(sh), 420, 446(sh) nm Diminishing with nm 
Methyl 9,12-linoleate (unconjugated) 358(sh), 372 nm Strong 
422 nm Moderate! y strong 
Gamma methyl 9,12-linoleate 370, 408(sh) nm Strong 
430, 444(sh), 482 Moderate! y strong 
Methyl 9,11-linoleate (conjugated) 360(sh), 372 nm Strong 
Methyl 10,12-linoleate (conjugated) 412(sh), 430, 450(sh) Strong 
Methyl linolenate 372, 402(sh) nm Strong 
426, 444(sh), 486(sh) nm Moderate! y strong 
Glycerol trilinoleinate 358(sh), 372 nm More intense than 
422 nm methyl ester 
Glycerol trilinolenate 372, 402(sh) nm More intense than 
426, 444(sh), 486(sh) nm methyl ester 
Methyl arachidonate 375, 422 nm Very strong 
490(sh), 528(sh) 480(sh), 528(sh) Weaker shoulders 
Methyl eicosopentaenoate 376, 422(sh), 444(sh), 488(sh), Very strong 
516(sh), 560(sh) nm Diminishing with nm 
Methyl docosohexaenoate 376, 422(sh), 444(sh), 486(sh), Very strong 
spectral acquisition times are on the order of 5 seconds and 
can be automated. An alternative to separating the precipi-
tate is to use simultaneous dual scan wavelength detection 
which factors out scattered light from suspended particles. 
Onset of color begins immediately the acid catalyst is added 65 
and continues rapidly with full development occurring 
within 8-15 minutes depending upon (a) the choice, and (b) 
512(sh), 540(sh), 562(sh) nm Diminishing with nm 
While the invention has been described with a certain 
degree of particularity, it is manifest that many changes may 
be made in the method without departing from the spirit and 
scope of this disclosure. It is understood that the invention 
is not limited to the embodiment set forth herein for the 
purpose of exemplification, but is to be limited only by the 
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scope of the attached claim or claims, including the full 
range of equivalency to which each step or element thereof 
is entitled. 
What is claimed is: 
5 1. A procedure for the simultaneous, comprehensive assay 
of unsaturated cyclic and open chain aliphatic molecular 
structures in a serum sample, comprising: 
(a) simultaneously acylating said structures using a chro-
mogenic reagent in a color reaction to obtain an acy- 10 
lated sample containing analogs of said structures; 
(b) measuring spectral characteristics of said sample over 
substantially the entire visible wavelength range to 
obtain multiplexed spectral data; and 
(c) developing a comprehensive serum lipids profile dis-
criminating among serum cholesterol and at least one 
15 
of the group consisting of free unsaturated long chain 
fatty acids (LCFA's), saturated and unsaturated 
cholesteryl-LCFA esters, and LCFA's in the form of 20 
triglycerides and phospholipids, by comparing said 
multiplexed spectral data with characteristics represen-
tative of known concentrations of said analogs. 
2. The procedure of claim 1, further comprising: 
25 (d) comparing said profile to a library of data represen-
tative of normal and abnormal values to diagnose or 
evaluate risk factors for disease. 
3. The procedure claim 2, wherein step (d) includes: 
14 
7. The procedure of claim 1, wherein step (b) includes: 
measuring the relative fluorescence of each analog in the 
acylated sample. 
8. The procedure of claim 1, wherein step (b) includes: 
measuring the spectral characteristics using circular 
dichroism. 
9. The procedure of claim 1, wherein step (c) includes: 
discriminating among chylomicron, VLDL, DL, LDL and 
HDL lipoprotein fractions and subfractions. 
10. The procedure of claim 1, wherein step (a) further 
comprises the substep of: 
(a)(l) after a predetermined time, eliminating further 
progress of said color reaction. 
11. The procedure of claim 10, wherein step (a)(l) 
includes: 
adding at a predetermined time an amount of glacial 
acetic acid sufficient to stop said color reaction. 
12. The procedure of claim 1, wherein step (b) further 
comprises the substep of: 
(b)(l) repeating step (b) at short time intervals after step 
(a) up to and including the end point of the color 
reaction in order to produce kinetic spectral data. 
13. The procedure of claim 1, wherein said chromogenic 
reagent is selected from the group consisting of acetyl 
chloride, acetic anhydride and glacial acetic acid and said 
color reaction is catalyzed by the addition of an acid selected 
from the group consisting of perchloric acid, zinc perchlo-
rate hexahydrate, concentrated sulfuric acid, methane-
comparing said profile to data representative of Type I, 
Ila, Ilb, III, IV and V dyslipidemias. 
3o sulfonic acid and zinc organic acid salts. 
4. The procedure of claim 2, wherein the disease 1s 
diabetes. 
5. The procedure of claim 2, wherein the disease 1s 
coronary artery disease. 
6. The procedure of claim 1, wherein step (b) includes: 
measuring the relative absorbance intensity of each ana-
log in the acylated sample. 
14. The procedure of claim 13, wherein said chromogenic 
reagent is acetyl chloride and said color reaction is catalyzed 
by the addition of a 70% perchloric acid solution. 
15. The procedure of claim 13, wherein said chromogenic 
35 reagent is acetyl chloride and said color reaction is catalyzed 
by the addition of a zinc perchlorate hexahydrate. 
* * * * * 
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